CN110751990A - 以ido1为靶点的抑制剂及其虚拟筛选方法 - Google Patents
以ido1为靶点的抑制剂及其虚拟筛选方法 Download PDFInfo
- Publication number
- CN110751990A CN110751990A CN201910990466.3A CN201910990466A CN110751990A CN 110751990 A CN110751990 A CN 110751990A CN 201910990466 A CN201910990466 A CN 201910990466A CN 110751990 A CN110751990 A CN 110751990A
- Authority
- CN
- China
- Prior art keywords
- compound
- screening
- dioxygenase
- small molecule
- indoleamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000003041 virtual screening Methods 0.000 title claims abstract description 24
- 239000003112 inhibitor Substances 0.000 title claims abstract description 23
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 title abstract description 42
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 title abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 238000012216 screening Methods 0.000 claims abstract description 39
- 150000003384 small molecules Chemical class 0.000 claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 230000004071 biological effect Effects 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims abstract description 7
- 239000003446 ligand Substances 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 13
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 13
- 238000003032 molecular docking Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000003064 k means clustering Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 230000006920 protein precipitation Effects 0.000 claims description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- -1 heterocyclic arenes Chemical class 0.000 description 23
- 238000002835 absorbance Methods 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical class OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 5
- 229940043367 IDO1 inhibitor Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002611 lead compounds Chemical class 0.000 description 3
- 241001120493 Arene Species 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- OBWYQBDZBORALQ-UHFFFAOYSA-N 1-[5-[benzyl(methyl)amino]-1,3,4-thiadiazol-2-yl]-3-(3,4,5-trimethoxyphenyl)urea Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)NC=2SC(=NN=2)N(C)CC=2C=CC=CC=2)=C1 OBWYQBDZBORALQ-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- CPIKQLSKHGJLGA-UHFFFAOYSA-N 2-(4h-chromeno[4,3-c]pyrazol-1-yl)-n-[3-(2-ethoxyphenyl)-1,2-oxazol-5-yl]acetamide Chemical compound CCOC1=CC=CC=C1C1=NOC(NC(=O)CN2C=3C4=CC=CC=C4OCC=3C=N2)=C1 CPIKQLSKHGJLGA-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1h-imidazole Chemical class N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 108010041382 compound 20 Proteins 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- NRNDMBZAQRJQGG-UHFFFAOYSA-N n-[4-(4-methylphenyl)-1,2-oxazol-5-yl]-2-[(4-oxo-6-pyridin-3-yl-1h-pyrimidin-2-yl)sulfanyl]acetamide Chemical compound C1=CC(C)=CC=C1C1=C(NC(=O)CSC=2NC(=CC(=O)N=2)C=2C=NC=CC=2)ON=C1 NRNDMBZAQRJQGG-UHFFFAOYSA-N 0.000 description 1
- 229950007250 navoximod Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
Landscapes
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Computing Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种以吲哚胺2,3双加氧酶1(IDO1)为靶点的抑制剂虚拟筛选方法及其应用,具体涉及以IDO1为靶点,利用配位键限制策略的虚拟筛选技术结合体外生物活性评价进行小分子抑制剂筛选的新方法。体外活性测试结果表明,本发明所述化合物对IDO1靶点表现出较强的抑制活性。本发明所述方法可以更有效和高命中率地获得具有IDO1抑制活性的化合物,所发现的化合物可进一步用于开发新型抗癌药物。
Description
技术领域
本发明属医药化学技术领域,涉及药物筛选方法,具体涉及利用配位键限制策略的虚拟筛选技术结合体外生物活性评价进行小分子抑制剂筛选的新方法,尤其涉及以吲哚胺2,3双加氧酶1(IDO1)为靶点的小分子抑制剂的虚拟筛选模型及体外模型的建立方法,应用该方法可以更有效和高命中率地获得的具有IDO1抑制活性的化合物,可进一步用于开发新型抗癌药物。
背景技术
吲哚胺2,3双加氧酶1(IDO1)催化色氨酸分解代谢的初始和限速步骤,导致色氨酸的消耗和犬尿氨酸代谢产物的产生,两者都有利于IDO1的免疫抑制能力。作为免疫反应内生的分子调节剂,IDO1可作为防止过量免疫活性和免疫病理学的检查点,癌细胞也有可能受益于IDO1的免疫抑制作用。新出现的证据表明IDO1是负责肿瘤逃避宿主免疫的免疫机制的重要调节因子。大量临床研究证明了IDO1基因的表达水平在多种肿瘤中上调,包括卵巢癌,子宫内膜癌,结直肠癌和肝细胞癌等。
目前,存在至少七种IDO1小分子抑制剂在临床开发中,如临床试验注册表ClinicalTrial.gov所示。其中,5种化学结构已公开。5类结构包括:(1)吲哚和[5,6]杂环芳烃,例如临床候选物吲哚莫德和PF-06840003,(2)羟胺类,例如临床候选者epacadostat,(3)4-苯基咪唑(4-PIs),如临床候选物 navoximod,(4)1,2-二氨基取代和1-羟基-2-氨基取代的芳烃,包括候选物 KHK2455,(5)其它如BMS类化合物,BMS-986205.
药物先导化合物的常规筛选方法是通过随机筛选,该方法需要合成或收集大量化合物,利用建立的药理筛选模型进行大量筛选,以期从中发现有潜力的化合物进入临床前研究。因为常规筛选的效率低、成本高,盲目性大,本领域迫切需要用高效、快速筛选方法,以满足IDO1抑制剂开发的需要。
随着分子模拟和计算化学在药物研发中的应用,虚拟筛选为先导化合物的发现提供了一种快速、高效的筛选技术。该技术针对重要疾病特定靶标生物大分子的三维结构,从现有小分子数据库中,搜寻与靶标结合较好的化合物,大大降低实验筛选化合物数量,缩短研发周期。因此,建立一种快速、高效的IDO1 抑制剂的虚拟筛选技术对于新骨架类型IDO1先导化合物的发现具有重要意义。
发明内容
本发明的目的在于提供一种快速、高效的IDO1抑制剂的虚拟筛选方法,并将其成功用于发现靶向IDO1的小分子抑制剂。
本发明的设计构思:首先利用分子对接程序对小分子化合物库中的化合物进行对接打分评价,在虚拟筛选过程中需要加入配位键限制,以提高虚拟筛选的命中率,通过对这些分子进行K-means clustering聚类,挑选出化合物在细胞水平进行验证,筛选出具有IDO1抑制活性的候选分子。
基于上述设计构思。本发明采用如下技术方案:
一种IDO1抑制剂的虚拟筛选方法,包括如下步骤:
(1)吲哚胺2,3双加氧酶三维结构的获取、分析及处理;
(2)建立对接用小分子配体库;
(3)基于步骤(1)获得的数据信息构建虚拟筛选系统;
(4)运用步骤(3)构建获得的虚拟筛选系统对步骤(2)中的小分子配体库进行筛选,获得备选小分子;
(5)针对步骤(4)获得的备选小分子进行生物活性测试;
(6)分子相似性检索:基于步骤(5)筛选获得的具有生物活性的先导骨架,在小分子配体库进行相似结构化合物的检索,搜索与先导骨架具有相似结构的分子。
本发明方法步骤(1)中,在蛋白数据库(https://www.rcsb.org/)中获得IDO1 的三维结构(PDB code:4PK5),该结构为IDO1与其抑制剂Amg-1的复合物 (Amg-1与IDO1的结合口袋如图1所示);使用薛定谔软件包中的 Maestro10.1(2015-01,version 10.1)的Proteinpreparation wizard模块进行准备,首先对蛋白进行加氢,并删除蛋白中的水分子,然后在OPLS_2005力场条件下对蛋白进行能量优化和最小化。
本发明方法步骤(2)中,建立对接小分子配体库;小分子结构在chemdiv 数据库中获取,使用薛定谔软件包中的Ligprep模块对配体进行优化,分别利用 Lipinski’s五规则,是否具有可反应基团,对化合物进行对接前筛选工作。
本发明方法步骤(3)中,使用薛定谔软件包中的Grid Generation以配体 Amg-1作为格点盒子生成格点文件,加入金属配位键限制。
本发明方法步骤(4)中,将准备的小分子配体与靶蛋白进行对接,首先使用薛定谔软件中Glide的HTVS(high-throughput virtual screening)模式进行初筛,并选取打分前10%的化合物用SP(standard precision)模式进行复筛,然后根据打分选取前10%的化合物用XP(extra precision)模式进行精筛,保留最后打分前30%的化合物(3800个),然后对这些分子用薛定谔软件包中Canvas2.3 模块进行K-means clustering聚类,最后根据打分、配体的结合构象对化合物进行挑选,并筛选出具有IDO1抑制活性的化合物。
本发明方法步骤(5)中,根据虚拟筛选结果挑选化合物进行生物活性测试,以Hela细胞测试,最终筛选出具有IDO1抑制活性的化合物。
本发明方法通过三轮虚拟筛选得到24个化合物,其中化合物1,2和8具有 1,3,4-噁二唑和脲基核心结构(化合物1,2,8与IDO1的结合模式如图2,3,4所示) 因此对化合物1进行相似性检索,对检索到的化合物进行细胞抑制活性测试,得到11个化合物1的衍生物具有较好的细胞抑制活性。总共得到了35个具有较好细胞抑制活性的化合物。活性化合物具有如下特征:
化合物-1
英文名称:
1-(3,4-dimethoxyphenyl)-3-(3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2-yl)phenyl)urea
化合物结构:
化合物-2
英文名称:
1-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(3,4-dimeth oxyphenyl)urea
化合物结构:
化合物-3
英文名称:
N-(3,4-dimethoxyphenyl)-2-(4-oxo-5-(p-tolyl)thieno[2,3-d]pyrimidin-3(4H)-yl)aceta mide
化合物结构:
化合物-4
英文名称:
5-(4-methoxyphenyl)-N-(3-methylphenethyl)oxazole-4-carboxamide
化合物架构:
化合物-5
英文名称:
2-(chromeno[4,3-c]pyrazol-1(4H)-yl)-N-(3-(2-ethoxyphenyl)isoxazol-5-yl)acetamide
化合物结构:
化合物-6
英文名称:
2-(pyridin-4-ylthio)-N-((6-(p-tolyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)aceta mide
化合物结构:
化合物-7
英文名称:
2-(benzo[d][1,3]dioxol-5-yloxy)-N-(5-phenethyl-1,3,4-thiadiazol-2-yl)acetamide
化合物结构:
化合物-8
英文名称:
ethyl3-(3-(3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2-yl)phenyl)ureido)propanoate
化合物结构:
化合物-9
英文名称:
N-(3-acetylphenyl)-2-((5-phenylthiazolo[2,3-c][1,2,4]triazol-3-yl)thio)acetami de
化合物结构:
化合物-10
英文名称:
1-(5-(benzyl(methyl)amino)-1,3,4-thiadiazol-2-yl)-3-(3,4,5-trimethoxyphenyl)urea
化合物结构:
化合物-11
英文名称:
2-((6-oxo-4-(pyridin-3-yl)-1,6-dihydropyrimidin-2-yl)thio)-N-(4-(p-tolyl)isoxazol-5- yl)acetamide
化合物结构:
化合物-12
英文名称:
5-cyano-2-((2-((4-methoxyphenyl)amino)-2-oxoethyl)thio)-4-oxo-6-phenyl-4,5-dihyd ropyrimidin-5-ide
化合物结构:
化合物-13
英文名称:
N-(4-acetylphenyl)-2-((5-(benzo[d][1,3]dioxol-5-yl)-1,3,4-oxadiazol-2-yl)thio)aceta mide
化合物结构:
化合物-14
英文名称:
3-chloro-2-methyl-N-(2-(5-(4-methylbenzyl)-1H-1,2,4-triazol-3-yl)ethyl)benzenesulf onamide
化合物结构:
化合物-15
英文名称:
N-(4-methoxyphenyl)-5-oxo-3-(p-tolyl)-5H-thiazolo[3,2-a]pyrimidine-6-carboxamid e
化合物结构:
化合物-16
英文名称:
2-(4-ethylphenoxy)-N-(4-(4-propoxyphenyl)-1,2,5-oxadiazol-3-yl)acetamide
化合物结构:
化合物-17
英文名称:
3-fluoro-N-(2-(3-(4-methylbenzyl)-1H-1,2,4-triazol-5-yl)ethyl)benzenesulfonamide
化合物结构:
化合物-18
英文名称:
N-(2-methoxyethyl)-5-oxo-3-(p-tolyl)-5H-thiazolo[3,2-a]pyrimidine-6-carboxamide
化合物结构:
化合物-19
英文名称:
N-(benzo[d][1,3]dioxol-5-ylmethyl)-3-((5-(4-chlorophenyl)thiazolo[2,3-c][1,2,4]triaz ol-3-yl)thio)propanamide
化合物结构:
化合物-20
英文名称:
3-chloro-4-fluoro-N-(2-(3-(4-methylbenzyl)-1H-1,2,4-triazol-5-yl)ethyl)benzenesulfo namide
化合物结构:
化合物-21
英文名称:
(E)-3-(2-((2-hydroxynaphthalen-1-yl)methylene)hydrazinecarbothioamido)benzoate
化合物结构:
化合物-22
英文名称:
3-chloro-N-(2-(5-(4-methylbenzyl)-1H-1,2,4-triazol-3-yl)ethyl)benzenesulfonamide
化合物结构:
化合物-23
英文名称:
N-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)-1,2,3-thiadiazole-5-carboxamide
化合物结构:
化合物-24
英文名称:
(S)-1-(5-phenyl-1H-tetrazol-1-yl)-3-((3,4,5-trimethoxyphenyl)amino)propan-2-ol
化合物结构:
化合物-25
英文名称:1-isobutyl-3-(3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2-yl)phenyl)urea
化合物结构:
化合物-26,L604-1256
英文名称:
1-(4-acetylphenyl)-3-(3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2-yl)phenyl)urea
化合物结构:
化合物-27,L150-0770
英文名称:
1-(4-fluoro-3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(4-fluorophenyl)ur ea
化合物结构:
化合物-28,L604-0616
英文名称:
ethyl 2-(3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2-yl)phenyl)ureido)acetate
化合物结构:
化合物-29
英文名称:
1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(3-(5-(4-methylbenzyl)-1,3,4-oxadiazol-2- yl)phenyl)urea
化合物结构:
化合物-30
英文名称:
1-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(3-methoxy phenyl)urea
化合物结构:
化合物-31
英文名称:
1-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(3-fluoro-4- methoxyphenyl)urea
化合物结构:
化合物-32
英文名称:
1-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(2-methoxy phenyl)urea
化合物结构:
化合物-33
英文名称:
1-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(2,3-dihydr obenzo[b][1,4]dioxin-6-yl)urea
化合物结构:
化合物-34
英文名称:
1-(3-acetylphenyl)-3-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)ph enyl)urea
化合物结构:
化合物-35英文名称:
1-(3-(5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3,4-oxadiazol-2-yl)phenyl)-3-(4-fluoroph enyl)urea
化合物结构:
本发明还公开了所述的虚拟筛选方法筛选出上述化合物在制备以吲哚胺2,3 双加氧酶为靶点的小分子抑制剂药物中的应用。
本发明还公开了所述的虚拟筛选方法筛选出上述化合物在制备抗癌药物中的应用。
本发明根据筛选结果挑选化合物进行生物活性测试。结果显示,筛选的化合物具有IDO1抑制活性(如表1所示),相似性检索的化合物也具有较好的IDO1 抑制活性(如表2所示),证明本发明的筛选方法具有有效性。筛选的具有IDO1 抑制活性的苗头化合物可进一步作为抗肿瘤药物进行开发。
表1筛选得到的24个化合物的理化性质和活性数据。
a:氢键供体b:氢键受体c:脂水分配系数d:可旋转键的数目e:分子量
试验中每个处理设两次重复,表中数据为两次重复的平均值,SD为标准偏差
表2显示了通过相似性检索得到的11个化合物1的衍生物的理化性质和活性数据。
表2
本发明的吲哚胺2,3双加氧酶1的筛选方法,具有快速、经济、高效的优势,为寻找吲哚胺2,3双加氧酶1小分子抑制剂提供了基础。
附图说明
图1,IDO1的活性口袋。
图2,IDO1蛋白的活性结合位点(包含抑制剂Amg-1)。
图3,化合物1与IDO1蛋白的对接图。
图4,化合物2与IDO1蛋白的对接图。
图5,化合物8与IDO1蛋白的对接图。
具体实施方式
实施例1
按下述步骤筛选以吲哚胺2,3双加氧酶1为靶点的小分子抑制剂,
(1)吲哚胺2,3双加氧酶1(IDO1)蛋白三维结构的获取、分析和处理;
在蛋白数据库(https://www.rcsb.org/)中获得吲哚胺2,3双加氧酶1的三维结构(PDB code:4PK5)该结构为IDO1与其抑制剂Amg-1的复合物;使用薛定谔软件包中的Protein preparation wizard模块进行准备,首先对蛋白进行加氢,并删除蛋白中的水分子,然后在OPLS_2005力场条件下对蛋白进行能量优化和最小化。
(2)构建及处理对接用小分子配体库;
建立对接小分子配体库;小分子结构在chemdiv数据库中获取,使用Ligprep模块对配体进行优化,分别利用Lipinski’s五规则,是否具有可反应基团,对化合物进行对接前的预处理。
(3)构建虚拟筛选系统
使用薛定谔软件包中的Grid Generation以配体Amg-1作为格点盒子生成格点文件,其中加入金属配位键限制。
(4)用步骤(3)的计算机筛选系统对步骤(2)中的小分子配体库进行筛选:将准备的小分子配体与靶蛋白进行对接,首先使用薛定谔软件中的Glide的HTVS(high-throughputvirtual screening)模式进行初筛,并选取打分前10%的化合物用SP(standardprecision)模式进行复筛,然后根据打分选取前10%的化合物用XP(extra precision)模式进行精筛,保留最后打分前30%的化合物(3800 个),然后对这些分子用薛定谔软件包中Canvas2.3模块进行K-means clustering 聚类,最后根据打分、配体的结合构象对化合物进行挑选,并筛选出具有吲哚胺2,3双加氧酶1抑制活性的苗头化合物。
(5)生物活性测试
为了进行基于HeLa细胞的IDO1抑制实验,以化合物BMS-986205化合物作为阳性对照,将HeLa细胞以50,000个细胞/孔接种到96孔微量培养板的100 μl生长培养基中,将细胞在37℃和5%CO 2下孵育过夜。第二天,100μL稀释抑制剂被加入生长培养基中的以使最终人IFNγ的浓度为100ng/mL。一系列的稀释液都是用0.1%DMSO配置,使得所有溶液中DMSO的浓度均为0.1%。将细胞在37℃下在CO2培养箱中温育24小时。第三天,将140μl培养夜移入新的96孔板中,并加入10μl的6.1N TCA,将孔板在50℃温育30分钟,以将IDO 产生的N-甲酰基犬尿氨酸水解成犬尿氨酸,然后将板以2500rpm离心10分钟以除去沉淀物。将每孔100μl上清液转移到另一个96孔板中并与100μl2%(w/ v)4-(二甲基氨基)苯甲醛在乙酸中混合,将板在室温下孵育10分钟,通过使用酶标仪((PerkinElmer,USA)测量480nm处的吸光度来记录来自犬尿氨酸的黄色。使用计算机软件Graphpad Prism分析吸光度数据。在不存在化合物和存在100ng/mLIFNγ的情况下,每个数据集中的吸光度(At)定义为100%,每个数据集中培养基空白(Ab)的吸光度定义为0%。根据下式计算每种化合物存在下的吸光度百分比:%吸光度=(A-Ab)/(At-Ab),其中A=化合物和 IFNγ存在下的吸光度,Ab=培养基空白吸光度,At=不存在化合物但存在IFN γ时的吸光度。使用GraphPad Prism 6.0软件计算IC50值。
(6)相似性检索
基于命中的先导骨架进行相似性检索,搜索到14个化合物1的类似物,与步骤(5)同样方法测出这些化合物的IC50,发现有11个类似物的IC50小于 100μM。(表2所示) 。
Claims (8)
1.一种以吲哚胺2,3双加氧酶为靶点的小分子抑制剂的筛选方法,其步骤包括:
(1)吲哚胺2,3双加氧酶三维结构的获取、分析及处理;
(2)建立对接用小分子配体库;
(3)基于步骤(1)获得的数据信息构建虚拟筛选系统;
(4)运用步骤(3)构建获得的虚拟筛选系统对步骤(2)中的小分子配体库进行筛选,获得备选小分子;
(5)针对步骤(4)获得的备选小分子进行生物活性测试;
(6)分子相似性检索:基于步骤(5)筛选获得的具有生物活性的先导骨架,在小分子配体库进行相似结构化合物的检索,搜索与先导骨架具有相似结构的分子。
2.如权利要求1所述的以吲哚胺2,3双加氧酶为靶点的小分子抑制剂的筛选方法,其特征在于,所述步骤(1)中,在蛋白数据库https://www.rcsb.org/中获得吲哚胺2,3双加氧酶的三维结构PDB code:4PK5,该结构为吲哚胺2,3双加氧酶与其抑制剂Amg-1的复合物;使用薛定谔软件包中的maestro10.1的Protein preparation wizard模块进行准备,首先对蛋白进行加氢,并删除蛋白中的水分子,然后在OPLS_2005力场条件下对蛋白进行能量优化和最小化。
3.如权利要求1所述的以吲哚胺2,3双加氧酶为靶点的小分子抑制剂的筛选方法,其特征在于,所述步骤(2)的建立对接小分子配体库中;小分子结构在chemdiv数据库中获取,使用薛定谔软件包中maestro10.1的Ligprep模块对配体进行优化,分别利用Lipinski’s五规则,是否具有可反应基团,对化合物进行对接前筛选工作。
4.如权利要求1所述的以吲哚胺2,3双加氧酶为靶点的小分子抑制剂的筛选方法,其特征在于,所述步骤(3)中,使用薛定谔软件包中maestro10.1中的Grid Generation以配体Amg-1作为格点盒子生成格点文件,其中加入金属配位键限制。
5.如权利要求1所述的以吲哚胺2,3双加氧酶为靶点的小分子抑制剂的筛选方法,其特征在于,所述步骤(4)中,将准备的小分子配体与靶蛋白进行对接,首先使用薛定谔软件中maestro10.1里的Glide的HTVS(high-throughput virtual screening)模式进行初筛,并选取打分前10%的化合物用SP(standard precision)模式进行复筛,然后根据打分选取前10%的化合物用XP(extra precision)模式进行精筛,保留最后打分前30%的化合物,然后对这些分子用薛定谔软件包中Canvas2.3模块进行K-means clustering聚类,最后根据打分、配体的结合构象对化合物进行挑选,并筛选出具有吲哚胺2,3双加氧酶抑制活性的化合物,化合物的结构特征如下所示:
7.权利要求1至6任一项所述的虚拟筛选方法筛选出的化合物在制备以吲哚胺2,3双加氧酶为靶点的小分子抑制剂药物中的应用。
8.权利要求1至6任一项所述的虚拟筛选方法筛选出的化合物在制备抗癌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910990466.3A CN110751990A (zh) | 2019-10-17 | 2019-10-17 | 以ido1为靶点的抑制剂及其虚拟筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910990466.3A CN110751990A (zh) | 2019-10-17 | 2019-10-17 | 以ido1为靶点的抑制剂及其虚拟筛选方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110751990A true CN110751990A (zh) | 2020-02-04 |
Family
ID=69278819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910990466.3A Pending CN110751990A (zh) | 2019-10-17 | 2019-10-17 | 以ido1为靶点的抑制剂及其虚拟筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110751990A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113421610A (zh) * | 2021-07-01 | 2021-09-21 | 北京望石智慧科技有限公司 | 一种分子叠合构象确定方法、装置以及存储介质 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107346379A (zh) * | 2016-05-07 | 2017-11-14 | 复旦大学 | 一种以组织蛋白酶d为靶点的小分子抑制剂的筛选方法 |
CN109748838A (zh) * | 2019-01-31 | 2019-05-14 | 中国科学院南海海洋研究所 | 蒽醌类化合物及其制备方法和在制备酶抑制剂中的应用 |
-
2019
- 2019-10-17 CN CN201910990466.3A patent/CN110751990A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107346379A (zh) * | 2016-05-07 | 2017-11-14 | 复旦大学 | 一种以组织蛋白酶d为靶点的小分子抑制剂的筛选方法 |
CN109748838A (zh) * | 2019-01-31 | 2019-05-14 | 中国科学院南海海洋研究所 | 蒽醌类化合物及其制备方法和在制备酶抑制剂中的应用 |
Non-Patent Citations (3)
Title |
---|
DINGDING GAO: "Identification and preliminary structure–activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1(IDO1) inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
GUOQING ZHANG: "Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening", 《FRONTIERS IN PHARMACOLOGY》 * |
张玉萍: "基于虚拟筛选发现4-羟基喹啉类新型IDO1抑制剂", 《第三军医大学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113421610A (zh) * | 2021-07-01 | 2021-09-21 | 北京望石智慧科技有限公司 | 一种分子叠合构象确定方法、装置以及存储介质 |
CN113421610B (zh) * | 2021-07-01 | 2023-10-20 | 北京望石智慧科技有限公司 | 一种分子叠合构象确定方法、装置以及存储介质 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gomes et al. | QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity | |
Huang et al. | Structure-based and ligand-based drug design for HER 2 receptor | |
Shahzad et al. | Synthesis and biological evaluation of novel oxadiazole derivatives: A new class of thymidine phosphorylase inhibitors as potential anti-tumor agents | |
Oyewole et al. | Theoretical calculations of molecular descriptors for anticancer activities of 1, 2, 3-triazole-pyrimidine derivatives against gastric cancer cell line (MGC-803): DFT, QSAR and docking approaches | |
CN110718268B (zh) | 虚拟筛选在制备蛋白激酶抑制剂的应用和药物先导化合物 | |
Shahzadi et al. | Synthesis, anticancer, and computational studies of 1, 3, 4‐oxadiazole‐purine derivatives | |
Chen et al. | Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity | |
La Pietra et al. | Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors | |
Noorulla et al. | Molecular modeling of drug-pathophysiological Mtb protein targets: Synthesis of some 2-thioxo-1, 3-thiazolidin-4-one derivatives as anti-tubercular agents | |
Bekhit et al. | New pyrazolylpyrazoline derivatives as dual acting antimalarial-antileishamanial agents: synthesis, biological evaluation and molecular modelling simulations | |
CN110751990A (zh) | 以ido1为靶点的抑制剂及其虚拟筛选方法 | |
Dunkern et al. | Virtual and experimental high-throughput screening (HTS) in search of novel inosine 5′-monophosphate dehydrogenase II (IMPDH II) inhibitors | |
Petrovic et al. | Virtual screening in the cloud identifies potent and selective ROS1 kinase inhibitors | |
Cheng et al. | Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network | |
Abd-Rabo et al. | Design, synthesis, and biological evaluation of some new 2-phenyl-3, 6-pyridazinedione derivatives as PDE-5 inhibitors | |
Alnabulsi et al. | Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling | |
Vats et al. | Keto-bridged dual triazole-linked benzenesulfonamides as potent carbonic anhydrase and cathepsin B inhibitors | |
Ren et al. | Homology modeling and virtual screening for inhibitors of lipid kinase PI (4) K from Plasmodium | |
Zhou et al. | Pharmacophore-based 3D-QSAR modeling, virtual screening and molecular docking analysis for the detection of MERTK inhibitors with novel scaffold | |
Lu et al. | Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1, 3-(2 H, 4 H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors | |
Khunt et al. | Synthesis and 3 D‐QSAR Analysis of 2‐Chloroquinoline Derivatives as H 37 RV MTB Inhibitors | |
Xie et al. | Structure‐based design of diarylpyrimidines and triarylpyrimidines as potent HIV‐1 NNRTIs with improved metabolic stability and drug resistance profiles | |
Bai et al. | Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety | |
Paliwal et al. | Pharmacophore and molecular docking based identification of novel structurally diverse PDE-5 inhibitors | |
da Silva Santos-Júnior et al. | A consensus reverse docking approach for identification of a competitive inhibitor of acetyltransferase enhanced intracellular survival protein from Mycobacterium tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200204 |